Notably, the coexpression of CD19 and CD138 might be detected in certain cases of LPL, B-CLL, ALL, and AML [8], as example in human ALL-derived REH cells herein, and hence, CAR-NK-92 cells targeting CD19 and CD138 may benefit those of hematologic malignancies as well. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.